Liquid biopsies (LBs), particularly using circulating tumor DNA (ctDNA), are expected to
revolutionize precision oncology and blood-based cancer screening. Recent technological …

Simple Summary Liquid biopsies provide a non-invasive means to diagnose and profile
tumors when tissue is not available. Sequence-based analysis of cell-free DNA (cfDNA) is …

Widespread adaptation of liquid biopsy for the early detection of cancer has yet to reach
clinical utility. Circulating tumor DNA is commonly detected though the presence of genetic …

Deeper and broader sequencing of circulating tumor DNA (ctDNA) has identified a wealth of
cancer markers in the circulation, resulting in a paradigm shift towards data science-driven …

Molecular analysis of cell-free DNA (cfDNA) that circulates in plasma and other body fluids
represents a “liquid biopsy” approach for non-invasive cancer screening or monitoring. The …

Liquid biopsies, in particular, analysis of cell-free DNA (cfDNA), have emerged as a
promising noninvasive diagnostic approach in oncology. Abnormal distribution of DNA …

Robust and clinically convenient biomarkers for cancer diagnosis, early detection, and
prognosis have great potential to improve patient survival and are the key to precision …

Cancer is a molecular disease associated with alterations in the genome, which, thanks to
the highly improved sensitivity of mutation detection techniques, can be identified in cell-free …

Circulating tumor DNA (ctDNA) in blood plasma is present at very low concentrations
compared to cell-free DNA (cfDNA) of non-tumor origin. To enhance ctDNA detection, recent …

Tissue biopsy is the standard diagnostic procedure for cancer. Biopsy may also provide
material for genotyping, which can assist in the diagnosis and selection of targeted therapies …